Tofacitinib

Tofacitinib has been studied in 8 papers since 2021: 1 trial and 3 observational studies in people, 2 in cells, 1 review; 3 in the past year. It is an approved medicine. The newest story, Oct 2, 2026: “Long-term human skin platform models chronic inflammation and senolytic treatments”.

InterventionApproved 2012

8 papers study it1 more mentions it9 findingsUpdated

PubChemChEBIMeSH

See all 9 papers on tofacitinib

At a glance

The findings reach people, from one lab or study. 4 independent labs in 3 countries; 144 trials, none about aging, 34 with no results posted.

“After 6 months, tofacitinib treatment was associated with significant increases in lower limb muscle volume (mean increase 242 cm3 [95% CI 44-441], p=0·017)”
Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine studyThe Lancet. Rheumatology2025doi:10.1016/s2665-9913(25)00184-5

None of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.
  • 4 independent labs in 3 countries
  • 144 trials, none about aging, 34 with no results posted
  • Funders: BMA Foundation for Medical Research and others
  • 5 of 9 findings with company ties
  • 58 of 144 trials sponsored by its developers
  • Human trial1
  • Humans3
  • Cells2

Studies in people

1 study gave tofacitinib to people and measured what changed.

What changedDesignPeopleSource

up: Increases lower limb muscle volumemean increase 242 cm3 [95% CI 44-441], p=0·017

up: Increases creatininep=0·0011

down: Decreases rheumatoid arthritisp=0·0064

Trial6 months15 peopleBoth59·6 yearsPatient cohortsThe Lancet. Rheumatology, Oct 15, 2025

What did studies of tofacitinib find?

7

Studies of tofacitinib measured 7 outcomes, among them cellular senescence, inflammation and muscle strength.

Cellular senescence

upin human cells1upin humans1

1 study
  1. Tofacitinib is linked with higher cellular senescence in rheumatoid arthritis patients.

    “tofacitinib led to an accumulation of peripheral senescent memory CD4+ and CD8+ T cells”

    Humansin rheumatoid arthritis patients

    Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro

    European journal of immunology

  2. Tofacitinib activates cellular senescence in human cells (upon TCR-engagement in vitro).

    “triggered senescence pathways in T-cell subsets upon TCR-engagement, with the most significant impact on memory CD8+ T cells”

    Cellsupon TCR-engagement in vitroT cell

    Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro

    European journal of immunology

More on Cellular senescence

Inflammation

downin human cells1

1 study
  1. Tofacitinib inhibits inflammation in human cells.

    “sustained IL-17/IL-22 stimulation over 3 weeks induced chronic inflammatory transcriptional programs, progressive histopathological changes, and persistent secretion of IL-8, MCP-1, S100A8/A9, and MMP-1, which was broadly suppressed by the Janus kinase inhibitor tofacitinib.”

    Cellsskin3 weeks

    Long-term human skin platform models chronic inflammation and senolytic treatments

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

More on Inflammation

Muscle strength

no changein humans1

1 study
  1. Tofacitinib showed no clear effect on muscle strength in humans (not significant).

    “No significant changes in appendicular lean mass index, muscle strength, or muscle function were observed.”

    Human trial6 monthsn = 15

    Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

    The Lancet. Rheumatology

Rheumatoid arthritis

downin humans1

1 study
  1. Tofacitinib decreases rheumatoid arthritis in humans (p=0·0064).

    “Disease activity (DAS28-CRP) was significantly reduced after 1 month of tofacitinib treatment (p=0·0064) with no further changes at 6 months.”

    Human trial1 monthn = 15

    Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

    The Lancet. Rheumatology

More on Rheumatoid arthritis

Creatinine

upin humans1

1 study
  1. Tofacitinib increases creatinine in humans (p=0·0011).

    “significant increases in serum creatinine (p=0·0011)”

    Human trial6 monthsn = 15

    Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

    The Lancet. Rheumatology

More on Creatinine

Lower limb muscle volume

upin humans1

1 study
  1. Tofacitinib increases lower limb muscle volume in humans (mean increase 242 cm3 [95% CI 44-441], p=0·017).

    “After 6 months, tofacitinib treatment was associated with significant increases in lower limb muscle volume (mean increase 242 cm3 [95% CI 44-441], p=0·017)”

    Human trialskeletal muscle6 monthsn = 15

    Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

    The Lancet. Rheumatology

Cell cycle regulation

downin human cells1

1 study
  1. Tofacitinib inhibits cell cycle regulation in human cells (upon TCR-engagement in vitro).

    “In vitro, tofacitinib impaired the activation, proliferation, and effector molecules expression and triggered senescence pathways in T-cell subsets upon TCR-engagement”

    Cellsupon TCR-engagement in vitroT cell

    Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro

    European journal of immunology

More on Cell cycle regulation

What is tofacitinib linked with?

1

Studies link tofacitinib with osteoporosis.

Osteoporosis

upin humans1

1 study
  1. Tofacitinib is associated with osteoporosis in humans (Disproportionality of spontaneous adverse-event reports) (ROR 3.65, 95% CI 3.00–4.40).

    “tofacitinib (3.65 [3.00-4.40])”

    HumansDisproportionality of spontaneous adverse-event reports

    Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

    Bone

More on Osteoporosis

Has tofacitinib been tested in people?

0 of 144 about aging

Yes: 1 trial and 3 observational studies in people have been published, and 137 trials are registered.

Approved

  • FDA Xeljanz

    Nov 6, 2012Arthritis, Psoriatic, Active Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Active Rheumatoid Arthritis, moderately to severely active ulcerative colitis

  • FDA Xeljanz XR

    Feb 23, 2016Arthritis, Psoriatic, Active Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Active Rheumatoid Arthritis, moderately to severely active ulcerative colitis

  • EMA Xeljanz

    Mar 22, 2017Arthritis, Rheumatoid, Arthritis, Psoriatic, polyarticular juvenile idiopathic arthritis, Active Rheumatoid Arthritis, juvenile psoriatic arthritis, moderately to severely active ulcerative colitis, Active Ankylosing Spondylitis

  • FDA Xeljanz

    Sep 25, 2020Arthritis, Psoriatic, Active Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Active Rheumatoid Arthritis, moderately to severely active ulcerative colitis

Repurposing

40 of 61

In trials

  • Alopecia universalis

    Phase 4Results posted4 trials

  • Rhematoid arthritis

    Phase 4Results posted1 trial

  • Autoimmune diseases of the nervous system

    Phase 2Completed1 trial

  • Extranodal NK/T-cell lymphoma

    Phase 2Status unknown1 trial

  • Lymphoma, large b-cell, diffuse

    Phase 2Status unknown1 trial

  • Pouchitis

    Phase 2Terminated1 trial

All 11

Stopped

  • NCT04311567TerminatedRheumatoid arthritis

    Low recruitment due to the pandemic and high screening failure rate in particular because of low prevalence of interstitial abnormalities at diagnosis in Sweden.

  • NCT04415151TerminatedCOVID-19 pneumonia

    Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.

  • NCT04580277TerminatedPouchitis

    low recruitment

  • NCT04141904TerminatedDepression

    Covid-19 pandemic

  • NCT03159936TerminatedDiscoid lupus erythematosus

    unable to identify additional subjects to qualify for enrollment

Who is developing tofacitinib?

3 companies: Takeda, Pfizer and CAGE Bio.

Companies
  • TakedaPhase 4ulcerative colitis
  • PfizerPhase 3ulcerative colitis, arthritis juvenile idiopathic
  • CAGE BioPhase 2atopic dermatitis

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 0Nov 2026: 03 papers in 12 months
Neurotherapeutics

Enzyme-blocking drugs linked to lower Parkinson disease risk

Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.

Case-control studyParkinson's disease